Search

Your search keyword '"Gladman, Dafna D"' showing total 113 results
Start Over Author "Gladman, Dafna D" Journal arthritis care & research
113 results on '"Gladman, Dafna D"'

1. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

Author

Legge, Alexandra, Kirkland, Susan, Rockwood, Kenneth, Andreou, Pantelis, Bae, Sang‐Cheol, Gordon, Caroline, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Wallace, Daniel J, Bernatsky, Sasha, Clarke, Ann E, Merrill, Joan T, Ginzler, Ellen M, Fortin, Paul R, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Isenberg, David A, Rahman, Anisur, Alarcón, Graciela S, Petri, Michelle, Khamashta, Munther A, Dooley, MA, Ramsey‐Goldman, Rosalind, Manzi, Susan, Zoma, Asad A, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Vollenhoven, Ronald F, Jonsen, Andreas, Nived, Ola, Ramos‐Casals, Manuel, Kamen, Diane L, Kalunian, Kenneth C, Jacobsen, Søren, Peschken, Christine A, Askanase, Anca, and Hanly, John G

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Lupus, Clinical Research, Autoimmune Disease, Inflammatory and immune system, Good Health and Well Being, Adult, Female, Frailty, Hospitalization, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Severity of Illness Index, Young Adult, Clinical Sciences, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveThe Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) predicts mortality and damage accrual in systemic lupus erythematosus (SLE), but its association with hospitalizations has not been described. Our objective was to estimate the association of baseline SLICC-FI values with future hospitalizations in the SLICC inception cohort.MethodsBaseline SLICC-FI scores were calculated. The number and duration of inpatient hospitalizations during follow-up were recorded. Negative binomial regression was used to estimate the association between baseline SLICC-FI values and the rate of hospitalizations per patient-year of follow-up. Linear regression was used to estimate the association of baseline SLICC-FI scores with the proportion of follow-up time spent in the hospital. Multivariable models were adjusted for relevant baseline characteristics.ResultsThe 1,549 patients with SLE eligible for this analysis were mostly female (88.7%), with a mean ± SD age of 35.7 ± 13.3 years and a median disease duration of 1.2 years (interquartile range 0.9-1.5) at baseline. Mean ± SD baseline SLICC-FI was 0.17 ± 0.08. During mean ± SD follow-up of 7.2 ± 3.7 years, 614 patients (39.6%) experienced 1,570 hospitalizations. Higher baseline SLICC-FI values (per 0.05 increment) were associated with more frequent hospitalizations during follow-up, with an incidence rate ratio of 1.21 (95% confidence interval [95% CI] 1.13-1.30) after adjustment for baseline age, sex, glucocorticoid use, immunosuppressive use, ethnicity/location, SLE Disease Activity Index 2000 score, SLICC/American College of Rheumatology Damage Index score, and disease duration. Among patients with ≥1 hospitalization, higher baseline SLICC-FI values predicted a greater proportion of follow-up time spent hospitalized (relative rate 1.09 [95% CI 1.02-1.16]).ConclusionThe SLICC-FI predicts future hospitalizations among incident SLE patients, further supporting the SLICC-FI as a valid health measure in SLE.

Published
2022

2. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications

Author

Bernatsky, Sasha, Ramsey‐Goldman, Rosalind, Urowitz, Murray B, Hanly, John G, Gordon, Caroline, Petri, Michelle A, Ginzler, Ellen M, Wallace, Daniel J, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine A, Isenberg, David A, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, S Sam, Vollenhoven, Ronald, Nived, Ola, Kamen, Diane L, Aranow, Cynthia, Ruiz‐Irastorza, Guillermo, Sánchez‐Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcón, Graciela S, Merrill, Joan T, Kalunian, Kenneth C, Ramos‐Casals, Manuel, Steinsson, Kristjan, Zoma, Asad, Askanase, Anca, Khamashta, Munther A, Bruce, Ian, Inanc, Murat, and Clarke, Ann E

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Oncology and Carcinogenesis, Clinical Research, Autoimmune Disease, Prevention, Lung, Patient Safety, Lung Cancer, Lupus, Rare Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Antimalarials, Female, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Neoplasms, Risk Factors, Smoking, Clinical Sciences, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveTo assess cancer risk factors in incident systemic lupus erythematosus (SLE).MethodsClinical variables and cancer outcomes were assessed annually among incident SLE patients. Multivariate hazard regression models (overall risk and most common cancers) included demographic characteristics and time-dependent medications (corticosteroids, antimalarial drugs, immunosuppressants), smoking, and the adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 score.ResultsAmong 1,668 patients (average 9 years follow-up), 65 cancers occurred: 15 breast, 10 nonmelanoma skin, 7 lung, 6 hematologic, 6 prostate, 5 melanoma, 3 cervical, 3 renal, 2 each gastric, head and neck, and thyroid, and 1 each rectal, sarcoma, thymoma, and uterine cancers. Half of the cancers (including all lung cancers) occurred in past/current smokers, versus one-third of patients without cancer. Multivariate analyses indicated that overall cancer risk was related primarily to male sex and older age at SLE diagnosis. In addition, smoking was associated with lung cancer. For breast cancer risk, age was positively associated and antimalarial drugs were negatively associated. Antimalarial drugs and higher disease activity were also negatively associated with nonmelanoma skin cancer risk, whereas age and cyclophosphamide were positively associated. Disease activity was associated positively with hematologic and negatively with nonmelanoma skin cancer risk.ConclusionSmoking is a key modifiable risk factor, especially for lung cancer, in SLE. Immunosuppressive medications were not clearly associated with higher risk except for cyclophosphamide and nonmelanoma skin cancer. Antimalarials were negatively associated with breast cancer and nonmelanoma skin cancer risk. SLE activity was associated positively with hematologic cancer and negatively with nonmelanoma skin cancer. Since the absolute number of cancers was small, additional follow-up will help consolidate these findings.

Published
2021

4. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Author

Clarke, Ann E., Hanly, John G., Urowitz, Murray B., St. Pierre, Yvan, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David A., Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., Dooley, Mary Anne, Ramsey‐Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S., Van Vollenhoven, Ronald F., Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S. Sam, Inanc, Murat, Kalunian, Kenneth C., Jacobsen, Soren, Peschken, Christine A., Kamen, Diane L., Askanase, Anca, and Farewell, Vernon

Published
2023
Full Text
View/download PDF

5. Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort

Author

Choi, May Y, Clarke, Ann E, St. Pierre, Yvan, Hanly, John G, Urowitz, Murray B, Romero‐Diaz, Juanita, Gordon, Caroline, Bae, Sang‐Cheol, Bernatsky, Sasha, Wallace, Daniel J, Merrill, Joan T, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Bruce, Ian N, Dooley, Mary A, Fortin, Paul R, Gladman, Dafna D, Sanchez‐Guerrero, Jorge, Steinsson, Kristjan, Ramsey‐Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Alarcón, Graciela S, Manzi, Susan, Nived, Ola, Zoma, Asad A, Vollenhoven, Ronald F, Ramos‐Casals, Manuel, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Soren, Askanase, Anca, Stoll, Thomas, Buyon, Jill, Mahler, Michael, and Fritzler, Marvin J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lupus, Autoimmune Disease, Inflammatory and immune system, Adult, Antibodies, Antinuclear, Biomarkers, Female, Fluorescent Antibody Technique, Indirect, Glucocorticoids, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Mitosis, Predictive Value of Tests, Prognosis, Serologic Tests, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveThe spectrum of antinuclear antibodies (ANAs) is changing to include both nuclear staining as well as cytoplasmic and mitotic cell patterns (CMPs) and accordingly a change is occurring in terminology to anticellular antibodies. This study examined the prevalence of indirect immunofluorescence (IIF) anticellular antibody staining using the Systemic Lupus International Collaborating Clinics inception cohort.MethodsAnticellular antibodies were detected by IIF on HEp-2000 substrate using the baseline serum. Three serologic subsets were examined: ANA positive (presence of either nuclear or mixed nuclear/CMP staining), anticellular antibody negative (absence of any intracellular staining), and isolated CMP staining. The odds of being anticellular antibody negative versus ANA or isolated CMP positive was assessed by multivariable analysis.ResultsA total of 1,137 patients were included; 1,049 (92.3%) were ANA positive, 71 (6.2%) were anticellular antibody negative, and 17 (1.5%) had an isolated CMP. The isolated CMP-positive group did not differ from the ANA-positive or anticellular antibody-negative groups in clinical, demographic, or serologic features. Patients who were older (odds ratio [OR] 1.02 [95% confidence interval (95% CI) 1.00, 1.04]), of white race/ethnicity (OR 3.53 [95% CI 1.77, 7.03]), or receiving high-dose glucocorticoids at or prior to enrollment (OR 2.39 [95% CI 1.39, 4.12]) were more likely to be anticellular antibody negative. Patients on immunosuppressants (OR 0.35 [95% CI 0.19, 0.64]) or with anti-SSA/Ro 60 (OR 0.41 [95% CI 0.23, 0.74]) or anti-U1 RNP (OR 0.43 [95% CI 0.20, 0.93]) were less likely to be anticellular antibody negative.ConclusionIn newly diagnosed systemic lupus erythematosus, 6.2% of patients were anticellular antibody negative, and 1.5% had an isolated CMP. The prevalence of anticellular antibody-negative systemic lupus erythematosus will likely decrease as emerging nomenclature guidelines recommend that non-nuclear patterns should also be reported as a positive ANA.

Published
2019

6. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

Author

Hanly, John G, Li, Qiuju, Su, Li, Urowitz, Murray B, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Fortin, Paul, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Steinsson, Kristjan, Ramsey‐Goldman, Rosalind, Zoma, Asad A, Manzi, Susan, Nived, Ola, Jonsen, Andreas, Khamashta, Munther A, Alarcón, Graciela S, Chatham, Winn, Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Ramos‐Casals, Manuel, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, Theriault, Chris, and Farewell, Vernon

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Autoimmune Disease, Clinical Research, Lupus, Hematology, Stroke, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system, Adult, Cerebrovascular Disorders, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Quality of Life, Young Adult, Clinical Sciences, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveTo determine the frequency, characteristics, and outcomes of cerebrovascular events (CerVEs), as well as clinical and autoantibody associations in a multiethnic/racial inception cohort of patients with systemic lupus erythematosus (SLE).MethodsA total of 1,826 patients were assessed annually for 19 neuropsychiatric (NP) events, including 5 types of CerVEs: 1) stroke, 2) transient ischemia, 3) chronic multifocal ischemia, 4) subarachnoid/intracranial hemorrhage, and 5) sinus thrombosis. Global disease activity (Systemic Lupus Erythematosus Disease [SLE] Activity Index 2000), damage scores (SLE International Collaborating Clinics/American College of Rheumatology Damage Index), and Short Form 36 (SF-36) scores were collected. Time to event, linear and logistic regressions, and multistate models were used as appropriate.ResultsCerVEs were the fourth most frequent NP event: 82 of 1,826 patients had 109 events; of these events, 103 were attributed to SLE, and 44 were identified at the time of enrollment. The predominant events were stroke (60 of 109 patients) and transient ischemia (28 of 109 patients). CerVEs were associated with other NP events attributed to SLE, non-SLE-attributed NP events, African ancestry (at US SLICC sites), and increased organ damage scores. Lupus anticoagulant increased the risk of first stroke and sinus thrombosis and transient ischemic attack. Physician assessment indicated resolution or improvement in the majority of patients, but patients reported sustained reduction in SF-36 summary and subscale scores following a CerVE.ConclusionCerVEs, the fourth most frequent NP event in SLE, are usually attributable to lupus. In contrast to good physician-reported outcomes, patients reported a sustained reduction in health-related quality of life following a CerVE.

Published
2018

7. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Author

Johnson, Sindhu R., Gladman, Dafna D., Brunner, Hermine I., Isenberg, David, Clarke, Ann E., Barber, Megan R. W., Arnaud, Laurent, Fortin, Paul R., Mosca, Marta, Voskuyl, Alexandre E., Manzi, Susan, Aranow, Cynthia, Askanase, Anca, Alarcón, Graciela S., Bae, Sang‐Cheol, Costedoat‐Chalumeau, Nathalie, English, Jessica A., Pons‐Estel, Guillermo J., Pons‐Estel, Bernardo A., Gilman, Rebecca, Ginzler, Ellen M., Hanly, John G., Jacobsen, Soren, Kalunian, Kenneth, Kamen, Diane L., Lambalgen, Chynace, Legge, Alexandra, Lim, S. Sam, Mak, Anselm, Morand, Eric F., Peschken, Christine A., Petri, Michelle, Rahman, Anisur, Ramsey‐Goldman, Rosalind, Reynolds, John A., Romero‐Diaz, Juanita, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Svenungsson, Elisabet, Touma, Zahi, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F., Waldhauser, Heather, Wallace, Daniel J., Zoma, Asad, and Bruce, Ian N.

Published
2023
Full Text
View/download PDF

8. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach

Author

Barber, Megan RW, Hanly, John G, Su, Li, Urowitz, Murray B, St. Pierre, Yvan, Romero‐Diaz, Juanita, Gordon, Caroline, Bae, Sang‐Cheol, Bernatsky, Sasha, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Bruce, Ian N, Fortin, Paul R, Gladman, Dafna D, Sanchez‐Guerrero, Jorge, Ramsey‐Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Mackay, Meggan, Alarcón, Graciela S, Manzi, Susan, Nived, Ola, Jönsen, Andreas, Zoma, Asad A, Vollenhoven, Ronald F, Ramos‐Casals, Manuel, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Soren, Askanase, Anca, Theriault, Chris, Farewell, Vernon, and Clarke, Ann E

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Lupus, Kidney Disease, Autoimmune Disease, Clinical Research, Burden of Illness, Renal and urogenital, Adult, Cohort Studies, Female, Health Care Costs, Humans, Lupus Nephritis, Male, Middle Aged, Models, Economic, Young Adult, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveLittle is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling.MethodsPatients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs associated with each renal state by the expected state duration.ResultsA total of 1,545 patients participated; 89.3% were women, the mean ± age at diagnosis was 35.2 ± 13.4 years, 49% were white, and the mean followup duration was 6.3 ± 3.3 years. LN developed in 39.4% of these patients by the end of followup. Ten-year cumulative costs were greater in those with LN and an estimated glomerular filtration rate (GFR) 60 ml/minute) or with LN and estimated proteinuria >3 gm/day ($84,040 versus $20,499 if no LN and estimated proteinuria

Published
2018

14. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling

Author

Clarke, Ann E., primary, Hanly, John G., additional, Urowitz, Murray B., additional, St. Pierre, Yvan, additional, Gordon, Caroline, additional, Bae, Sang‐Cheol, additional, Romero‐Diaz, Juanita, additional, Sanchez‐Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J., additional, Isenberg, David A., additional, Rahman, Anisur, additional, Merrill, Joan T., additional, Fortin, Paul R., additional, Gladman, Dafna D., additional, Bruce, Ian N., additional, Petri, Michelle, additional, Ginzler, Ellen M., additional, Dooley, Mary Anne, additional, Ramsey‐Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S., additional, Van Vollenhoven, Ronald F., additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz‐Irastorza, Guillermo, additional, Lim, S. Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C., additional, Jacobsen, Soren, additional, Peschken, Christine A., additional, Kamen, Diane L., additional, Askanase, Anca, additional, and Farewell, Vernon, additional

Published
2023
Full Text
View/download PDF

15. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Author

Johnson, Sindhu R., primary, Gladman, Dafna D., additional, Brunner, Hermine I., additional, Isenberg, David, additional, Clarke, Ann E., additional, Barber, Megan R. W., additional, Arnaud, Laurent, additional, Fortin, Paul R., additional, Mosca, Marta, additional, Voskuyl, Alexandre E., additional, Manzi, Susan, additional, Aranow, Cynthia, additional, Askanase, Anca, additional, Alarcón, Graciela S., additional, Bae, Sang‐Cheol, additional, Costedoat‐Chalumeau, Nathalie, additional, English, Jessica A., additional, Pons‐Estel, Guillermo J., additional, Pons‐Estel, Bernardo A., additional, Gilman, Rebecca, additional, Ginzler, Ellen M., additional, Hanly, John G., additional, Jacobsen, Soren, additional, Kalunian, Kenneth, additional, Kamen, Diane L., additional, Lambalgen, Chynace, additional, Legge, Alexandra, additional, Lim, S. Sam, additional, Mak, Anselm, additional, Morand, Eric F., additional, Peschken, Christine A., additional, Petri, Michelle, additional, Rahman, Anisur, additional, Ramsey‐Goldman, Rosalind, additional, Reynolds, John A., additional, Romero‐Diaz, Juanita, additional, Ruiz‐Irastorza, Guillermo, additional, Sanchez‐Guerrero, Jorge, additional, Svenungsson, Elisabet, additional, Touma, Zahi, additional, Urowitz, Murray, additional, Vinet, Evelyne, additional, van Vollenhoven, Ronald F., additional, Waldhauser, Heather, additional, Wallace, Daniel J., additional, Zoma, Asad, additional, and Bruce, Ian N., additional

Published
2022
Full Text
View/download PDF

17. Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria

Author

Petri, Michelle, primary, Goldman, Daniel W., additional, Alarcón, Graciela S., additional, Gordon, Caroline, additional, Merrill, Joan T., additional, Fortin, Paul R., additional, Bruce, Ian N., additional, Isenberg, David, additional, Wallace, Daniel, additional, Nived, Ola, additional, Ramsey‐Goldman, Rosalind, additional, Bae, Sang‐Cheol, additional, Hanly, John G., additional, Sanchez‐Guerrero, Jorge, additional, Clarke, Ann E., additional, Aranow, Cynthia, additional, Manzi, Susan, additional, Urowitz, Murray, additional, Gladman, Dafna D., additional, Kalunian, Ken, additional, Werth, Victoria P., additional, Zoma, Asad, additional, Bernatsky, Sasha, additional, Khamashta, Munther, additional, Jacobsen, Søren, additional, Buyon, Jill P., additional, Dooley, Mary Anne, additional, van Vollenhoven, Ronald, additional, Ginzler, Ellen, additional, Stoll, Thomas, additional, Peschken, Christine, additional, Jorizzo, Joseph L., additional, Callen, Jeffery P., additional, Lim, Sam, additional, Inanç, Murat, additional, Kamen, Diane L., additional, Rahman, Anisur, additional, Steinsson, Kristjan, additional, Franks, Andrew G., additional, and Magder, Laurence S., additional

Published
2021
Full Text
View/download PDF

18. The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA–B27 Status?

Author

Coates, Laura C., primary, Baraliakos, Xenofon, additional, Blanco, Francisco J., additional, Blanco‐Morales, Elena Alonso, additional, Braun, Jurgen, additional, Chandran, Vinod, additional, Fernandez‐Sueiro, Jose Luis, additional, FitzGerald, Oliver, additional, Gallagher, Phil, additional, Gladman, Dafna D., additional, Gubar, Elena, additional, Korotaeva, Tatiana, additional, Loginova, Elena, additional, Lubrano, Ennio, additional, Mulero, Juan, additional, Pinto‐Tasende, Jose, additional, Queiro, Ruben, additional, Sanz Sanz, Jesús, additional, Szentpetery, Agnes, additional, and Helliwell, Philip S., additional

Published
2021
Full Text
View/download PDF

19. Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population‐Based Study

Author

Eder, Lihi, primary, Tu, Karen, additional, Rosen, Cheryl F., additional, Alhusayen, Raed, additional, Cheng, Stephanie Y., additional, Young, Jacqueline, additional, Campbell, Willemina, additional, Bernatsky, Sasha, additional, Gladman, Dafna D., additional, Paterson, J. Michael, additional, and Widdifield, Jessica, additional

Published
2021
Full Text
View/download PDF

20. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach

Author

Barber, Megan R. W., primary, Hanly, John G., additional, Su, Li, additional, Urowitz, Murray B., additional, St. Pierre, Yvan, additional, Romero‐Diaz, Juanita, additional, Gordon, Caroline, additional, Bae, Sang‐Cheol, additional, Bernatsky, Sasha, additional, Wallace, Daniel J., additional, Merrill, Joan T., additional, Isenberg, David A., additional, Rahman, Anisur, additional, Ginzler, Ellen M., additional, Petri, Michelle, additional, Bruce, Ian N., additional, Dooley, Mary A., additional, Fortin, Paul R., additional, Gladman, Dafna D., additional, Sanchez‐Guerrero, Jorge, additional, Steinsson, Kristjan, additional, Ramsey‐Goldman, Rosalind, additional, Khamashta, Munther A., additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Alarcón, Graciela S., additional, Manzi, Susan, additional, Nived, Ola, additional, Jönsen, Andreas, additional, Zoma, Asad A., additional, van Vollenhoven, Ronald F., additional, Ramos‐Casals, Manuel, additional, Ruiz‐Irastorza, Guillermo, additional, Lim, S. Sam, additional, Kalunian, Kenneth C., additional, Inanc, Murat, additional, Kamen, Diane L., additional, Peschken, Christine A., additional, Jacobsen, Søren, additional, Askanase, Anca, additional, Farewell, Vernon, additional, Stoll, Thomas, additional, Buyon, Jill, additional, and Clarke, Ann E., additional

Published
2020
Full Text
View/download PDF

21. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

Author

Helliwell, Philip S., primary, Deodhar, Atul, additional, Gottlieb, Alice B., additional, Boehncke, Wolf-Henning, additional, Xu, Xie L., additional, Xu, Stephen, additional, Wang, Yuhua, additional, Hsia, Elizabeth C., additional, Gladman, Dafna D., additional, and Ritchlin, Christopher T., additional

Published
2020
Full Text
View/download PDF

22. Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations

Author

Mease, Philip J., primary, Gladman, Dafna D., additional, Ogdie, Alexis, additional, Coates, Laura C., additional, Behrens, Frank, additional, Kavanaugh, Arthur, additional, McInnes, Iain, additional, Queiro, Rubén, additional, Guerette, Benoit, additional, Brunori, Michele, additional, Teng, Lichen, additional, and Smolen, Josef S., additional

Published
2020
Full Text
View/download PDF

24. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies

Author

Gladman, Dafna D., primary, Charles‐Schoeman, Christina, additional, McInnes, Iain B., additional, Veale, Douglas J., additional, Thiers, Bruce, additional, Nurmohamed, Mike, additional, Graham, Dani, additional, Wang, Cunshan, additional, Jones, Thomas, additional, Wolk, Robert, additional, and DeMasi, Ryan, additional

Published
2019
Full Text
View/download PDF

25. Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population‐Based Study

Author

Eder, Lihi, primary, Widdifield, Jessica, additional, Rosen, Cheryl F., additional, Cook, Richard, additional, Lee, Ker‐Ai, additional, Alhusayen, Raed, additional, Paterson, Michael J., additional, Cheng, Stephanie Y., additional, Jabbari, Shirin, additional, Campbell, Willemina, additional, Bernatsky, Sasha, additional, Gladman, Dafna D., additional, and Tu, Karen, additional

Published
2019
Full Text
View/download PDF

27. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Author

Singh, Jasvinder A., primary, Guyatt, Gordon, additional, Ogdie, Alexis, additional, Gladman, Dafna D., additional, Deal, Chad, additional, Deodhar, Atul, additional, Dubreuil, Maureen, additional, Dunham, Jonathan, additional, Husni, M. Elaine, additional, Kenny, Sarah, additional, Kwan‐Morley, Jennifer, additional, Lin, Janice, additional, Marchetta, Paula, additional, Mease, Philip J., additional, Merola, Joseph F., additional, Miner, Julie, additional, Ritchlin, Christopher T., additional, Siaton, Bernadette, additional, Smith, Benjamin J., additional, Van Voorhees, Abby S., additional, Jonsson, Anna Helena, additional, Shah, Amit Aakash, additional, Sullivan, Nancy, additional, Turgunbaev, Marat, additional, Coates, Laura C., additional, Gottlieb, Alice, additional, Magrey, Marina, additional, Nowell, W. Benjamin, additional, Orbai, Ana‐Maria, additional, Reddy, Soumya M., additional, Scher, Jose U., additional, Siegel, Evan, additional, Siegel, Michael, additional, Walsh, Jessica A., additional, Turner, Amy S., additional, and Reston, James, additional

Published
2018
Full Text
View/download PDF

29. Reply

Author

Urowitz, Murray B., primary and Gladman, Dafna D., additional

Published
2017
Full Text
View/download PDF

34. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Author

Singh, Jasvinder A., Guyatt, Gordon, Ogdie, Alexis, Gladman, Dafna D., Deal, Chad, Deodhar, Atul, Dubreuil, Maureen, Dunham, Jonathan, Husni, M. Elaine, Kenny, Sarah, Kwan‐Morley, Jennifer, Lin, Janice, Marchetta, Paula, Mease, Philip J., Merola, Joseph F., Miner, Julie, Ritchlin, Christopher T., Siaton, Bernadette, Smith, Benjamin J., and Van Voorhees, Abby S.

Subjects
ANTIRHEUMATIC agents, BIOLOGICAL products, COMBINATION drug therapy, COMPARATIVE studies, IMMUNOSUPPRESSIVE agents, RESEARCH methodology, MEDICAL cooperation, MEDICAL protocols, PSORIATIC arthritis, RESEARCH, RHEUMATOLOGY, EVALUATION research, TREATMENT effectiveness
Abstract

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations.Results: The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment.Conclusion: The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort

Author

Bourré‐Tessier, Josiane, primary, Urowitz, Murray B., additional, Clarke, Ann E., additional, Bernatsky, Sasha, additional, Krantz, Mori J., additional, Huynh, Thao, additional, Joseph, Lawrence, additional, Belisle, Patrick, additional, Bae, Sang‐Cheol, additional, Hanly, John G., additional, Wallace, Daniel J., additional, Gordon, Caroline, additional, Isenberg, David, additional, Rahman, Anisur, additional, Gladman, Dafna D., additional, Fortin, Paul R., additional, Merrill, Joan T., additional, Romero‐Diaz, Juanita, additional, Sanchez‐Guerrero, Jorge, additional, Fessler, Barri, additional, Alarcón, Graciela S., additional, Steinsson, Kristján, additional, Bruce, Ian N., additional, Ginzler, Ellen, additional, Dooley, Mary Anne, additional, Nived, Ola, additional, Sturfelt, Gunnar, additional, Kalunian, Kenneth, additional, Ramos‐Casals, Manuel, additional, Petri, Michelle, additional, Zoma, Asad, additional, and Pineau, Christian A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results